Genscript Biotech Corporation

Equities

1548

KYG3825B1059

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
14.5 HKD +2.11% Intraday chart for Genscript Biotech Corporation -6.57% -26.99%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Genscript Biotech's US Unit Secures FDA Nod for Anti-Cancer Medication MT
Genscript Biotech Issues 444,598 Shares to Three Grantees Under Restricted Share Scheme MT
Genscript Biotech's 2023 Loss Widens; Misses Revenue Estimates MT
Transcript : Genscript Biotech Corporation, 2023 Earnings Call, Mar 11, 2024
Genscript Biotech Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board CI
GenScript Biotech Corporation Expands Collaboration with Roche CI
Genscript Biotech Unit Rakes in $159 Million in Sales for Myeloma Treatment; Shares Rise 4% MT
Genscript Biotech Unit to Submit More Data to European, US Authorities for Approval of Myeloma Drug MT
Genscript, Legend Biotech On-Track to Begin Production at Ghent Facilities This Year MT
Genscript Biotech's Subsidiary Legend Closes License Agreement with Novartis for Anti-Cancer Drug MT
Genscript Biotech Unit Secures US FDA Nod for Carvykti Label Update MT
Genscript Biotech's Controlling Shareholder Sells 0.4% Stake to Hillhouse Unit MT
Genscript Biotech Controlling Shareholder Disposes of 8.6 Million Shares MT
Genscript Biotech's US Subsidiary Presents Positive Results of Carvykti Drug from Phase 3 Study MT
Genscript Subsidiary Legend Biotech Grants Novartis License to Develop Anti-Cancer Drug MT
Genscript Biotech's Carvykti Rakes in $152 Million in Q3 Net Trade Sales; Shares Fall 5% MT
Hong Kong Stocks Gain on China's Better-Than-Expected Industrial Data; China Evergrande Slumps 19% MT
GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services CI
Transcript : Genscript Biotech Corporation, Q2 2023 Earnings Call, Aug 21, 2023
Genscript Biotech Corporation Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Genscript Biotech's Q2 Attributable Loss Widens; Shares Fall 3% MT
GenScript Biotech Corporation Expands Peptide Production Capabilities to Include Neoantigen Peptides and APIs CI
Hong Kong Stocks Snap Three-Day Loss; Genscript Biotech Jumps 13% MT
China shares flat as support for auto, electronics fail to lift sentiment; HK shares up RE
Chart Genscript Biotech Corporation
More charts
Genscript Biotech Corporation is a Hong Kong-based investment holding company principally engaged in life science research and related businesses. The Company operates through four segments. Life Sciences Research Services segment includes gene and peptide synthesis, deoxyribonucleic acid (DNA) and primer synthesis, DNA sequencing, customized antibody production, protein expression and the production of stable cell lines. Preclinical Drug Development Services segment includes protein and antibody engineering, the study of in vitro drug and the study of in vivo drug. Life Sciences Research Catalog Products segment provides antibodies, recombinant proteins, equipment for protein isolation and analysis, molecular biology reagents, peptide, biochemicals and stable cell lines. Industrial Synthetic Biology Products segment is engaged in the development and production of industrial enzymes.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
1.815 USD
Average target price
3.688 USD
Spread / Average Target
+103.18%
Consensus
  1. Stock
  2. Equities
  3. Stock Genscript Biotech Corporation - Hong Kong S.E.
  4. News Genscript Biotech Corporation
  5. Genscript Biotech's Nasdaq-Listed Unit Secures Supply Deal for Cancer Drug With Janssen